Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Journal Article

Canadian study of health and aging: study methods and prevalence of dementia

CMAJ March 15, 1994 150 (6) 899-913;
  • Article
  • Responses
  • Metrics
Loading

Abstract

OBJECTIVE: To estimate the prevalence of dementia and its subtypes by sex and age group for five regions of Canada. DESIGN: Prevalence survey. SETTING: Community and institutional settings in Canada, excluding those in the two territories, Indian reserves and military units. PARTICIPANTS: Representative sample of people aged 65 and over interviewed between February 1991 and May 1992. Those in the community (9008 subjects) were chosen randomly from medicare lists in nine provinces or from the Enumeration Composite Record in Ontario. People in institutions (1255) were randomly selected from residents in stratified random samples of institutions in each region. INTERVENTIONS: Screening with the Modified Mini-Mental State (3MS) Examination to identify cognitive impairment. Clinical examination of all those in institutions, those in the community with a 3MS score of less than 78 and a sample of those in the community with a 3MS score of 78 or more to diagnose dementia. Dementia and Alzheimer's disease were defined according to established criteria. MAIN OUTCOME MEASURES: Prevalence of dementia of all types, by region, sex and age group, the estimated number of cases in the population by type of dementia and the age-standardized rate per 1000 population. RESULTS: The prevalence estimates suggested that 252,600 (8.0%) of all Canadians aged 65 and over met the criteria for dementia (95% confidence interval [CI] 236,800 to 268,400). These were divided roughly equally between the community and institutional samples; the female:male ratio was 2:1. The age-standardized rate ranged from 2.4%, among those aged 65 to 74 years, to 34.5%, among those aged 85 and over. The corresponding figures for Alzheimer's disease were 5.1% overall (161,000 cases; 95% CI 148,100 to 173,900), ranging from 1.0% to 26.0%; for vascular dementia it was 1.5% overall, ranging from 0.6% to 4.8%. If the prevalence estimates remain constant, the number of Canadians with dementia will rise to 592,000 by 2021. CONCLUSIONS: These Canadian estimates of the prevalence of dementia fall toward the upper end of the ranges in other studies, whereas the estimates for Alzheimer's disease fall in the middle of the ranges. This may suggest an unusual balance between Alzheimer's and other forms of dementia in the Canadian population.

  • Copyright © 1994 by Canadian Medical Association
PreviousNext
Back to top

In this issue

CMAJ
Vol. 150, Issue 6
15 Mar 1994
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Canadian study of health and aging: study methods and prevalence of dementia
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Canadian study of health and aging: study methods and prevalence of dementia
CMAJ Mar 1994, 150 (6) 899-913;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Canadian study of health and aging: study methods and prevalence of dementia
CMAJ Mar 1994, 150 (6) 899-913;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Informative Frailty Indices from Binarized Biomarkers
  • Generating synthetic aging trajectories with a weighted network model using cross-sectional data
  • Assessing care models implemented in primary healthcare for persons with dementia: a mixed-methods study protocol
  • Impact of the Quebec Alzheimer Plan on the detection and management of Alzheimer disease and other neurocognitive disorders in primary health care: a retrospective study
  • Probing the network structure of health deficits in human aging
  • Prevalence and management of dementia in primary care practices with electronic medical records: a report from the Canadian Primary Care Sentinel Surveillance Network
  • Utility of Hippocrates' prognostic aphorism to predict death in the modern era: prospective cohort study
  • Subtle Post-Procedural Cognitive Dysfunction After Atrial Fibrillation Ablation
  • Neuropathologic features associated with Alzheimer disease diagnosis: Age matters
  • Care and outcomes in patients with ischemic stroke with and without preexisting dementia
  • Nontraditional risk factors combine to predict Alzheimer disease and dementia
  • Communicating with families of dementia patients: Practical guide to relieving caregiver stress
  • Impact of Androgen-Deprivation Therapy on Cognitive Function in Men With Nonmetastatic Prostate Cancer
  • Omega-3 fatty acids and risk of dementia: the Canadian Study of Health and Aging
  • Does a single-item measure of depression predict mortality?
  • Does Executive Function Explain the IQ-Mortality Association? Evidence from the Canadian Study on Health and Aging
  • Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease
  • No advantage of A{beta}42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies
  • Diagnosis and treatment of dementia: Introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia
  • Joint effect of stroke and APOE 4 on dementia risk: The Canadian Study of Health and Aging
  • Cerebrovascular disease and dementia
  • Losing your mind
  • Preclinical Vascular Cognitive Impairment and Alzheimer Disease: Neuropsychological Test Performance 5 Years Before Diagnosis
  • Maladie d'Alzheimer
  • Dropouts and refusals in observational studies: Lessons for prevention trials.
  • Predictors of driving cessation in mild-to-moderate dementia.
  • Brain estrogen deficiency accelerates A{beta} plaque formation in an Alzheimer's disease animal model
  • A global clinical measure of fitness and frailty in elderly people
  • Apolipoprotein E {epsilon}4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging
  • Homocysteine and cognitive function in elderly people
  • Variations in case definition affect prevalence but not outcomes of mild cognitive impairment
  • Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis
  • Combination hormone replacement therapy and dementia
  • Knowledge of the legislation governing proxy consent to treatment and research
  • Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials
  • Cognitive Impairment in Heart Failure: Issues of Measurement and Etiology
  • The value of clock drawing in identifying executive cognitive dysfunction in people with a normal Mini-Mental State Examination score
  • Neuropsychological Predictors of Incident Dementia in Patients With Vascular Cognitive Impairment, Without Dementia
  • Societal Costs of Vascular Cognitive Impairment in Older Adults
  • Well-Being After Stroke in Canadian Seniors: Findings From the Canadian Study of Health and Aging
  • Past exposure to vaccines and subsequent risk of Alzheimer's disease
  • Prevalence of cognitive impairment: Data from the Indianapolis Study of Health and Aging
  • Assessment of health economics in Alzheimer's disease (AHEAD): Galantamine treatment in Canada
  • Progression of impairment in patients with vascular cognitive impairment without dementia
  • Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology
  • Prevalence of AD among whites: A summary by levels of severity
  • The incidence of dementia in Canada
  • Vascular Dementia : Incidence and Risk Factors in the Canadian Study of Health and Aging
  • Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian Study of Health and Aging
  • Prevalence and outcomes of vascular cognitive impairment
  • Causes of Alzheimer's disease
  • Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging
  • ApoE genotype in relation to AD and cholesterol: A study of 2,326 Chinese adults
  • Mortality in elderly Canadians with and without dementia: A 5-year follow-up
  • Interhemispheric disconnection syndrome in Alzheimer's disease
  • Relationship Between ApoE, MRI Findings, and Cognitive Function in the Cardiovascular Health Study
  • The Canadian Study of Health and Aging : Risk Factors for Vascular Dementia
  • Surgery in the elderly patient: a time for reappraisal
  • Google Scholar

More in this TOC Section

  • PEI's fixed link to mainland a living laboratory for occupational medicine
  • Impact on health care adds to the social cost of homelessness, MDs say
  • Bioethics for clinicians: 6. Advance care planning
Show more Journal Article

Similar Articles

Collections

  • Topics
    • Dementia & Alzheimer disease

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

CMA Civility, Accessibility, Privacy

 

Powered by HighWire